NCT04723810 TumorGlow Intraoperative Molecular Imaging (IMI)
| NCT ID | NCT04723810 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | University of Pennsylvania |
| Condition | Tumor, Solid |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2024-08-14 |
| Primary Completion | 2027-01-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 500 participants in total. It began in 2024-08-14 with a primary completion date of 2027-01-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a Phase 1/2 study in patients presenting with any solid tumor and/or diseased tissue even benign nodules presumed to be resectable and at risk for recurrence on pre-operative assessment who are considered to be good surgical candidates to evaluate the safety and efficacy of the image-guided surgery using indocyanine green for intramolecular imaging of solid tumors.
Eligibility Criteria
Inclusion Criteria: * Adult patients 18 years of age or older. * Patients presenting with any solid tumor and/or diseased tissue even benign nodules presumed to be resectable and at risk for recurrence on pre-operative assessment. * Good operative candidate as determined by the treating physician and/or multidisciplinary team. * Subject capable of giving informed consent. Exclusion Criteria: * Subject unable to participate in the consent process. * Vulnerable population including pregnant women, prisoners, and children. * History of uncontrolled hypertension (e.g., history of an ER admission for hypertensive crisis or ≥ 3 blood pressure medications) * Patients with a self-reported history of iodide allergies.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04723810 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Tumor, Solid. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT04723810 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT04723810 currently recruiting?
Yes, NCT04723810 is actively recruiting participants. Contact the research team at azra.din@pennmedicine.upenn.edu for enrollment information.
Where is the NCT04723810 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT04723810 clinical trial?
NCT04723810 is sponsored by University of Pennsylvania. The trial plans to enroll 500 participants.